Filing Flows › Arbutus Biopharma (ABUS) › Recalls, complaints & regulation
Arbutus Biopharma (ABUS): clinical trials
Arbutus Biopharma (ABUS) beyond its filings: 1 active clinical trial.
Arbutus Biopharma's latest quarter
Arbutus Biopharma, Q2 2026: revenue $1.0M (-91% year over year), operating margin -588.2%, net loss $5.1M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Arbutus Biopharma have?
1 active study on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.